2 years on: Deborah discusses her venetoclax trial and becoming MRD negative
Deborah Henderson et al.
iwNHL 2016 highlights: CAR T-cell therapy, DLBCL and new technologies
'Off the shelf' virus-specific T cells
The success of Phase III TOWER trial of blinatumomab in ALL
Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells